RGENREPLIGEN CORP

Nasdaq repligen.com


$ 164.85 $ -0.61 (-0.37 %)    

Thursday, 09-May-2024 15:59:52 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 164.89
$ 164.16
$ 0.00 x 0
$ 0.00 x 0
$ 161.93 - $ 166.37
$ 110.45 - $ 211.13
419,611
na
9.32B
$ 1.16
$ 628.04
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 04-27-2022 03-31-2022 10-Q
10 02-17-2022 12-31-2021 10-K
11 10-28-2021 09-30-2021 10-Q
12 07-27-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 10-31-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-01-2019 12-31-2018 10-K
23 11-01-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 03-17-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-repligen-lowers-price-target-to-200

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 t...

 repligen-q1-2024-adj-eps-028-misses-030-estimate-sales-151346m-beat-150062m-estimate

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.30 by 6...

 aehr-test-systems-reports-preliminary-results-joins-dyne-therapeutics-united-airlines-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

 whats-going-on-with-life-science-focused-repligen-stock-today

Repligen posts Q4 2023 results. CEO Tony Hunt highlights order strength in Filtration and Analytics. Positive momentum in new m...

 repligen-q4-adjusted-eps-033-inline-sales-15574m-beat-15539m-estimate

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.33 per share which met the analyst consensus estimate. This is a 51.47...

 earnings-scheduled-for-february-21-2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

 keybanc-maintains-overweight-on-repligen-raises-price-target-to-220

Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $210 to $220.

 why-intel-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth q...

 booz-allen-hamilton-posts-upbeat-results-joins-appfolio-gentex-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.

 analyst-ratings-for-repligen
Analyst Ratings For Repligen
12/20/2023 21:00:49

 jp-morgan-maintains-overweight-on-repligen-raises-price-target-to-210

JP Morgan analyst Tycho Peterson maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $170 to...

 benchmark-downgrades-repligen-to-hold

Benchmark analyst Robert Wasserman downgrades Repligen (NASDAQ:RGEN) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION